A genetic test tied to Alzheimer’s risk can now use urine, plasma or dried blood spots
Niki BioSolutions (NASDAQ: NIKI) announced that its subsidiary DiamiR Biosciences received NYSDOH CLEP approval to expand its APOE Genotyping test to include urine, plasma, and dried blood spots. The test, which identifies genetic variants linked to Alzheimer’s risk, was previously approved for blood, buccal swab, saliva, and tissue. The expansion allows for more accessible testing, including at-home or point-of-care sample collection, and supports integrated genetic and biomarker workflows.
How this was made
The 30-second read
Why it matters
The CLEP approval broadens sample types, potentially increasing test volume and positioning Niki ahead of peers lacking such flexibility.
Market read
First‑report regulatory clearance could drive near‑term share appreciation for NIKI and influence the broader genetic‑testing market.
What to watch
Implementation costs for new collection kits and potential need for payer coverage negotiations could delay upside.
Background
Niki BioSolutions (NASDAQ:NIKI) develops genomic and biomarker tests. Its APOE genotyping is used for Alzheimer’s risk assessment.
Ticker impact
Niki BioSolutions received NYSDOH CLEP approval to expand APOE genotyping to urine, plasma and dried blood spots, a new regulatory clearance.
likely upward pressure as market prices in broader sample options and potential sales lift.
First‑report of CLEP expansion; adds new specimen types, reducing collection barriers and opening new market segments.
Market effects
May encourage other genetic‑testing firms to seek similar specimen expansions, raising competitive pressure in neuro‑degenerative diagnostics.
Enhances Niki's service offering in New York and nationwide, potentially increasing US market share.
Sets a precedent for regulatory bodies to accept non‑blood specimens for APOE testing, influencing global labs.
Counterpoint
If reimbursement rates for urine/plasma APOE tests are low, the expanded panel may not translate into meaningful revenue.
Key entities
- companyNiki BioSolutions, Inc.
Clinical-stage life‑sciences company offering APOE genotyping.
- subsidiaryDiamiR Biosciences Corp.
Wholly‑owned lab unit that performed the test.
- regulatorNew York State Department of Health (NYSDOH)
Issued the CLEP test approval.
